HC Wainwright set a $2.00 price objective on RegeneRx Biopharmaceuticals Inc (NASDAQ:RGRX) in a research report sent to investors on Tuesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Shares of RegeneRx Biopharmaceuticals (NASDAQ RGRX) opened at 0.28 on Tuesday. The company’s 50 day moving average is $0.27 and its 200 day moving average is $0.28. RegeneRx Biopharmaceuticals has a one year low of $0.22 and a one year high of $0.40. The company has a market cap of $29.93 million and a P/E ratio of 25.45.

ILLEGAL ACTIVITY WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/30/regenerx-biopharmaceuticals-inc-rgrx-given-a-2-00-price-target-by-hc-wainwright-analysts.html.

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.

Receive News & Stock Ratings for RegeneRx Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc and related stocks with our FREE daily email newsletter.